Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor and is the only selective M4 PAM in clinical development. The molecule has shown promising early results in schizophrenia with several Ph. II trials enrolling and is intended to be developed for Alzheimer’s Disease psychosis as [...]
< 1 minute read
Mar. 14, 2023
Emraclidine: a Selective Positive Allosteric Modulator of the Cholinergic M4 Muscarinic Receptor
Cerevel/Pfizer M4 positive allosteric modulator
oral, QD M4 PAM Ph. II for schizophrenia discovery not disclosed emraclidine (CVL-231) Cerevel Therapeutics, Cambridge, MA; Pfizer, New York, NY